

145. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. *Lancet* 1994; **344**: 1255-60.
146. Chang AE, Schnieder PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomised trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. *Ann Surg* 1987; **206**: 685-93.
147. Hohn DC, Stagg RJ, Friedman MA, *et al.* A randomised trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group Trial. *J Clin Oncol* 1989; **7**: 1646-54.
148. Kemeny D, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. *Ann Intern Med* 1987; **107**: 459-65.
149. Martin JK, O'Connell MJ, Wieand HS, *et al.* Intra-arterial floxuridine- vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomised trial. *Arch Surg* 1990; **125**: 1022-7.
150. Rougier P, Ducreux M, Pignon JP, *et al.* Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. *Eur J Cancer* 1991; **27**: 1226-30.
151. Zalberg J, Cunningham D, Green M, *et al.* The final results of a large phase II study of the potent thymidylate synthase (TS) inhibitor Tomudex (ZD1694) in advanced colorectal cancer. *Proc Am Soc Clin Oncol* 1995; **14**: 204 (Abstract).
152. Cunningham D, Zalberg J, Francois E, *et al.* Tomudex (ZD1694) a new thymidylate synthase inhibitor with good antitumor activity in advanced colorectal cancer (ACC). *Proc Am Soc Clin Oncol* 1994; **13**: 199 (Abstract).
153. Rougier P, Bugat R, Douillard JY, *et al.* Phase II study of Irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. *J Clin Oncol* 1997; **15**: 251-60.
154. Becouarn Y, Ychou M, Ducreux M, *et al.* Oxaliplatin(L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. *Proc Am Soc Clin Oncol* 1997; **16**: 229 (Abstract).
155. Diaz-Rubio E, Marty M, Extra JM, *et al.* Multicentric phase II study with oxaliplatin (L-OHP) in 5-FU refractory patients with advanced colorectal cancer (ACC). *Proc Am Soc Clin Oncol* 1995; **14**: 209 (Abstract).
156. Bajetta E, Colleoni M, Di Bartolomeo M, *et al.* Doxifluridine: an active agent in advanced colorectal cancer (CRC). *Proc Am Soc Clin Oncol* 1994; **13**: 192 (Abstract).
157. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. *Cancer* 1994; **74**: 416-23.
158. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. *Cancer* 1990; **66**: 1387-91.
159. Sainsbury R, Haward B, Rider L, Johnston C, Round C. Influence of clinician workload and patterns of treatment on survival from breast cancer. *Lancet* 1995; **345**: 1265-70.

EDITORIAL

'Highwayman'

This issue contains the first of an occasional series of short 'filler' reviews of World Wide Web English Language Internet sites of utility and interest to European Surgical Oncologists.

Unlike books, web sites change rapidly in time and format, and we are currently witnessing an explosion in numbers of sites and in their content. The most sophisticated sites now represent a wealth of resources and interconnections to other sites, and are a powerful tool for communication and for professional development.

A well-constructed web site may include information about the host institution itself, and will direct the reader to related sites. The reader will be able to print out or download information from the site, or to send electronic mail from within their browser software to key personnel at the host institution.

Readers of the *European Journal of Surgical Oncology* are invited to submit short reviews, preferably of 200 words or less, of web sites which they judge to be of interest. The

selected web site may be a major gateway to cancer resources, or it may be an obscure site containing unique information or insights.

Each web site should be evaluated according to data structure, to presentation and ease of use; to quality and breadth of content and hence to professional utility; to topicality of content and frequency of revision and update; and to ease and speed of access across the Net.

For those readers who have yet to experience the enormous resources and the intellectual exhilaration of the World Wide Web, we hope that these short pieces will identify ports of entry to a brave new professional world. For the technical sophisticates, we hope to identify new routes across the electronic frontier. The Web is a dynamic world which we will never be able fully to chart and travel. Nevertheless, there are now many marvels to visit and savour!

David A. Rew, MA, MChir, FRCS

*Senior Lecturer and Honorary Consultant Surgeon,
University of Leicester,
Information Technology Editor*